While many patients benefit from conventional transplants, certain immune cells can still drive complications like chronic GVHD.
At Orca Bio, we’re advancing high-precision allogeneic cell therapy approaches designed to improve post-transplant outcomes. lnkd.in/gRbbgRe4
#CellTherapy #Hematology
Lauren Smith, Orca Bio’s Chief Quality Officer, will speak on the Women in Leadership panel at the 9th Annual American Pharma Manufacturing and Outsourcing Summit. It will cover navigating career challenges and the importance of building strong networks to shape impactful careers. bit.ly/4p8j65U
It's #NationalMarrowAwarenessMonth, a time to celebrate the donors who make life-saving treatments possible & the patients, families & care teams whose courage & support inspires our work.
Join registries like @nmdp-org.bsky.social & you could be the match that gives someone a 2nd chance at life.
We are pleased to announce that Orca Bio will present new clinical data on our investigational high-precision cell therapies at the 67th American Society of Hematology Annual Meeting.
More on our #ASH25 presentations can be found here: bit.ly/47oB7qI
#bloodcancer #hematology #celltherapy
Orca-T, our investigational allogeneic T-cell immunotherapy, is a finalist in the Biotech Innovation category of the Fierce Innovation Awards: Life Sciences Edition 2025!
This award recognizes the innovations pushing science forward. To learn more: orcabio.com
#FierceLifeSciencesAwards
#TeamOrcaBio joined Blood Cancer United's #LightTheNight Silicon Valley. #LightTheNight provides a powerful platform to stand in solidarity with the community and raise critical funds. We are proud to partner with Blood Cancer United in our shared vision of ending blood cancer as we know it today!
Today, Orca Bio announced the FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Orca-T to treat hematological malignancies.
Read more in the press release: bit.ly/4q1Uzkw
#cansky #medsky #hemonc
Orca Bio is proud to partner with NMDP and was honored to support this year’s Gala.
We had the privilege of witnessing a patient and donor meeting for the first time - a powerful reminder of the lives touched by this important cause and of the shared mission that unites us.
#cansky #medsky #hemonc
Last week, Team Orca Bio was on the ground in Houston, TX for the @societyofhemonc.bsky (SOHO) Annual Meeting to share results from the phase 3 study of our investigational T-cell immunotherapy, Orca-T.
#cansky #medsky #SOHO2025 #hemonc
This Blood Cancer Awareness Month, we join our partner Blood Cancer United in recognizing unmet needs across blood cancers and uniting for patients, families and caregivers.
BloodCancerUnited.org
#BCAM #cansky #medsky #celltherapy #AML
Orca Bio looks forward to presenting data on our investigational T-cell immunotherapy, Orca-T, at the upcoming @societyofhemonc.bsky.social Annual Meeting in Houston, Texas.
#cansky #medsky #SOHO2025 #hemonc
Our CEO, Nathaniel Fernhoff, recently joined Erin Harris on an episode of Cell & Gene: The Podcast to talk about Orca Bio’s journey – from foundational research to advancing our lead investigational cell therapy, and the path toward potential commercialization: bit.ly/4fDkf28
#cansky #medsky
Hi! We're excited to join the #Oncsky community. In 1H 2025, we shared the pivotal Phase 3 study results evaluating Orca-T, our lead investigational allogeneic T-cell immunotherapy, and announced the appointment of senior leaders as we advance toward commercialization. Stay tuned!
#cansky #medsky
